Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson innovative Medicine — Research and development expense ($M) ($M)
Form 10-Q / 10-K Segment Note
Latest, FY2025
11,827
Period ended Dec 28, 2025
Change on a year earlier
-12.6%
13,529 in FY2024
History
5 years
Since FY2019
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Innovative Medicine — Research and development expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 11,827 | -12.6% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 13,529 | +13.1% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 11,963 | +2.8% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 11,642 | – | Form 10-K (filed 2025-02-13) ↗ |
| FY2019 | Dec 29, 2019 | 300 | – | Form 10-K (filed 2022-02-17) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson Innovative Medicine — Research and development expense ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg_rd_im
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.